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Abstract
Background: The mechanisms responsible for the cardiovascular mortality in type I diabetes (DM) have not been
defined completely. We have shown in conscious dogs with DM that: 1) baseline coronary blood flow (CBF) was
significantly decreased, 2) endothelium-dependent (ACh) coronary vasodilation was impaired, and 3) reflex
cholinergic NO-dependent coronary vasodilation was selectively depressed. The most likely mechanism responsible
for the depressed reflex cholinergic NO-dependent coronary vasodilation was the decreased bioactivity of NO from
the vascular endothelium. The goal of this study was to investigate changes in cardiac gene expression in a canine
model of alloxan-induced type 1 diabetes.
Methods: Mongrel dogs were chronically instrumented and the dogs were divided into two groups: one normal
and the other diabetic. In the diabetic group, the dogs were injected with alloxan monohydrate (40-60 mg/kg iv)
over 1 min. The global changes in cardiac gene expression in dogs with alloxan-induced diabetes were studied
using Affymetrix Canine Array. Cardiac RNA was extracted from the control and DM (n = 4).
Results: The array data revealed that 797 genes were differentially expressed (P < 0.01; fold change of at least ±2).
150 genes were expressed at significantly greater levels in diabetic dogs and 647 were significantly reduced. There
was no change in eNOS mRNA. There was up regulation of some components of the NADPH oxidase subunits
(gp91 by 2.2 fold, P < 0.03), and down-regulation of SOD1 (3 fold, P < 0.001) and decrease (4 - 40 fold) in a large
number of genes encoding mitochondrial enzymes. In addition, there was down-regulation of Ca2+ cycling genes
(ryanodine receptor; SERCA2 Calcium ATPase), structural proteins (actin alpha). Of particular interests are genes
involved in glutathione metabolism (glutathione peroxidase 1, glutathione reductase and glutathione S-transferase),
which were markedly down regulated.
Conclusion: our findings suggest that type I diabetes might have a direct effect on the heart by impairing NO
bioavailability through oxidative stress and perhaps lipid peroxidases.
Background
Diabetes mellitus (DM) is a multifactorial disease which
is characterized by hyperglycemia, lipoprotein abnormal-
ities [1] and altered intermediary metabolism of major
food substrates [2]. In addition, the generation of free
radicals often worsens the complications of DM such as
hypertension, atherosclerosis and microcirculatory disor-
ders [3,4]. Changes in lipid levels and consequent disor-
ders of lipid metabolism and stress have been observed
in DM [5]. Due to altered intermediary metabolism in
DM, a feature present in both type 1 and type 2 DM,
patients with type 2 DM, even in the absence of clinical
cardiovascular disease, have a reduced maximal oxygen
consumption compared with non-diabetic people [6].
On the other hand, several studies have reported that
the basal metabolic rate is increased in diabetic states
[7,8]. This increase is a reflection of the increased meta-
bolic demands in DM.
Diabetes mellitus is usually associated with coronary
artery disease. Since the discovery of nitric oxide (NO),
a number of studies have revealed impaired endothe-
lium-dependent vasorelaxation in diabetic animals
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[9,10]. Our previous study [11] has indicated that reflex,
NO-dependent coronary vasodilation is depressed in
conscious dogs after the development of alloxan-induced
diabetes, suggesting a reduced ability of coronary blood
vessels to produce NO. Furthermore, in another study
[12], we have shown that: 1) kallikrein causes a decrease
in O2 consumption in cardiac muscle from normal dogs,
which is mediated by kinin and NO mechanisms; and 2)
the modulation of O2 consumption by endogenous NO
is depressed in cardiac muscle from diabetic dogs,
whereas the modulation of O2 consumption by exogen-
ous NO is still preserved. The mechanism responsible
for the depressed modulation of O2 consumption by
endogenous NO is likely because of the decreased
release of NO from the vascular endothelium rather
than mitochondrial dysfunction. Various studies have
shown that there is also evidence for mitochondrial dys-
function in the heart from the diabetic rat and mouse
[13-16]. In addition, another study by Linke et al [17]
showed significant changes in the myocardial substrate
(glucose) utilization in dogs only in the late stage of dia-
betes at a time when myocardial NO production is
already decreased. DNA microarrays have been used in
every aspect of biological and medical research, includ-
ing obesity and type 2 diabetes mellitus (T2D) in human
and various small animal models [18]. Therefore, we
sought to investigate cardiac gene expression changes in
a canine model of alloxan-induced type 1 diabetes. We
subsequently, compared and contrasted these changes to
the cardiac functional and metabolic effects that we pre-
viously observed.
Methods
Surgical instrumentation and in vivo protocol
The protocols were approved by the Institutional Ani-
mal Care and Use Committee of New York Medical
College and conform to the guiding principles for the
use and care of laboratory animals of the National Insti-
tutes of Health and the American Physiological Society.
The loss of body weight in the diabetic dogs was specifi-
cally discussed at the meeting of the Institutional Ani-
mal Care and Use Committee. Dogs were weighed every
other day.
Surgical Preparation
Male Mongrel dogs (24.5-29 kg body wt, n = 8) were
premedicated with acepromazine (0.3 mg/kg im) and
anesthetized with pentobarbital sodium (25 mg/kg iv). A
thoracotomy was performed, and instruments were
implanted for measurement of pressure, flow, and blood
sampling as described previously [11].
Induction of Diabetes in Conscious Dogs
The protocol used for these groups of control and dia-
betic dogs was the same as reported in our previous stu-
dies [11,12,17]. Mongrel dogs were chronically
instrumented for measurements of systemic hemody-
namics. The control hemodynamics were recorded
10-14 days after the surgery. After the control recording,
the dogs were divided into two groups: one normal
(n = 4) and the other diabetic (n = 4). In the diabetic
group, the dogs were injected with alloxan monohydrate
(40-60 mg/kg iv) over 1 min. Alloxan was prepared as a
5% solution in citrate buffer (pH 4-4.5). Blood gases and
plasma glucose were measured on days 3 and 7 after
alloxan injection. In some dogs whose plasma glucose
levels were below 200 mg/dl at day 3 after injection of
alloxan, a second injection of alloxan was given. Only
dogs with blood glucose >200 mg/dl (fasted for at least
16 h) on day 7 were included in the diabetic group.
Before and after the development of diabetes, the dogs
had free access to water. Systemic hemodynamics were
measured again after 3-5 wk. For microarray analysis,
DM dogs were sacrificed at 4 weeks after alloxan injec-
tion and the LV of the heart was harvested and stored
at -80°C for only two weeks before RNA isolation was
performed and sent to microarray facility for quality
control, labeling and hybridization to Affymetric
microarray.
Recording Techniques
Arterial pressure, LV pressure, left circumflex coronary
blood flow (CBF), and internal diameters were mea-
sured; heart rate (HR), mean arterial pressure, and mean
CBF were derived in conscious dogs, as we described
previously [11]. Measurements were recorded continu-
ously throughout the course of the experiment. Baseline
measurements were taken after the dog was resting
quietly on the table for 40 min.
RNA isolation
Total cardiac RNA was extracted at the same time from
left ventricular tissue of control (n = 4), and DM dogs
(n = 4) with a commercial RNA isolation kit using Tri-
zol (TRI REAGENT, Sigma, Saint Louis Missouri) as
described previously [19,20]. RNA samples were stored
at -80°C for two weeks before microarray labeling and
hybridization. Two quality control measures are carried
out on a small aliquot of the isolated RNA samples: 1) a
spectrophotometric analysis to confirm the concentra-
tion and to detect contaminating proteins and other
molecules, and 2) a size fractionation procedure using
the Agilent Bioanalyzer 2100 (Agilent Technologies) to
determine whether the RNA is intact. The later was per-
formed at the Bionomics Research and Technology Cen-
ter (BRTC), Rutgers University.
Microarray labeling and hybridization
The microarray labeling and hybridization procedures
were carried out at the Bionomics Research and Tech-
nology Center (BRTC), Rutgers University. The
Ojaimi et al. Cardiovascular Diabetology 2010, 9:43
http://www.cardiab.com/content/9/1/43
Page 2 of 10
microarray labeling, hybridization and analysis proce-
dures were described previously in detail [19]. In brief,
each individual sample was subjected to gene expression
analysis via the Affymetrix Canine Genome Array,
which was subsequently processed and scanned accord-
ing to the manufacturer’s instructions. The GeneChip®
Canine Genome Array was the first available commer-
cial canine expression array and contains over 23,813
Canis familiaris probe sets to monitor gene expression
for over 16,000 Canis familiaris full length transcripts.
Microarray data analysis
All arrays referred to in this study were assessed for
“array performance” prior to data analysis. This process
involved the statistical analysis of control transcripts that
are spiked into the samples themselves and the hybridiza-
tion cocktail to assess array performance. In addition,
several genes have been identified on each array to help
assess the overall quality of signal intensity from all
arrays. The results of this analysis were helpful to validate
the reproducibility of each array at baseline, allowing us
to define the lower level of sensitivity sufficient to iden-
tify small changes in biologically relevant genes.
Prior to analysis, data from each hybridization were
processed using Microarray Suite software, v 5.0 (MAS
5.0) to yield average difference values corresponding to
signal intensity for each probe-set. Distinct algorithms
were used to determine the absolute call, which distin-
guishes the presence or absence of a transcript, the dif-
ferential change in gene expression (increase (I),
decrease (D), marginal increase (MI), marginal decrease
(MD), and no change (NC)), and the magnitude of
change, which is represented as signal log ratio (on a
log base 2 scale). In brief, the algorithm which defines
the presence or absence of a gene takes into considera-
tion several qualitative and quantitative metrics from
the raw data set. T-tests were performed on the normal-
ized signal values prior to exploring additional analyses.
All the hybridization data have been submitted to the
National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus database GEO: http://www.
ncbi.nlm.nih.gov/geo with GEO Accession Numbers for
series GSE14887. The raw pixels data were imported
into GeneTraffic MULTI and all subsequent analyses
were performed on a GeneTraffic server (GeneTraffic v.
v. 3.2-11, Iobion Informatics, La Jolla, CA). All the
microarray data were analyzed and normalized using a
Robust Multi-Chip Analysis algorithm (RMA). The aver-
age of all the control animal data sets was used as the
baseline for the analysis.
Statistical Analysis
Hemodynamic data were expressed as mean ± SEM and
compared by one-way ANOVA followed by Dunnet’s
test. For the microarray analysis, statistical significance
for changes in gene expression was performed in Gene-
Traffic using a two-class method (t-test) and with var-
iance stabilization. Due to the overwhelming amount of
information generated from microarray analysis, differ-
ences were considered statistically significant at a nom-
inal significance of P ≤ 0.01 and at least ± 2 -fold
change in expression between control and DM dogs.
However, for a subset of genes of interest (such as
gp91), we considered P ≤ 0.05 as a significant value.
Results
Hemodynamics and cardiac function
The hemodynamic data for these dogs were measured in
this study and they were similar to our previously
reported data [11,12,17]. In our previous studies; we
have shown that insulin levels in plasma were signifi-
cantly decreased, whereas glucose levels in plasma were
significantly increased during the development of dia-
betes (all P < 0.05). In this current study with new
group of animals, we also showed that induction of dia-
betes mellitus increased arterial glucose levels from 74 ±
2 to 291 ± 32 at week 1, to 310 ± 33 at week 2, to 317 ±
41 at week 3, and to 279 ± 43 at week 4, respectively
(P < 0.05 vs. control) similar to our previous data [17].
Furthermore, dogs had clinical signs of diabetes, i.e.,
polyuria, polydipsia and weight loss (25.1 ± 0.7 to 20.5 ±
0.9 kg at week 4).
In addition, our current data showed that LVSP was
reduced (125 ± 6 mmHg to 107 ± 8 mmHg) and LV
dP/dt did not change from control (2762 ± 216 to 2374
± 343 mmHg/s) during diabetes. MAP decreased gradu-
ally, and this reduction reached statistical significance
102 ± 7 to 91 ± 6 mmHg at week 4. Moreover, at week
4 of diabetes, heart rate and mean CBF were signifi-
cantly diminished ( 28 ± 5 ml/min to 18 ± 4 ml/min)
and (100 ± 7 to 76 ± 14 beats/min), respectively, com-
pared with control (P < 0.05).
Global gene transcript profiling
Our microarray analysis was performed on heart tissues
taken at 4 weeks after induction of DM. From our cur-
rent and previously published data [17], this is the time
when glucose uptake was low. Earlier times were mainly
fueled by keto-acid uptake. When statistical analysis was
performed using P ≤ 0.01 and ± 2.0 fold change in com-
parison to the control group, our result showed that 797
genes were differentially expressed in DM in comparison
to control dogs. Of these, 150 genes were expressed at
significantly greater levels in diabetic dogs and 647 were
significantly reduced. For a full list of differentially
expressed genes see additional file 1, Table S1. Unfortu-
nately, about half of the genes in the dog genome
remain unidentified, due to the lack of annotation.
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When considering the identified genes, we found that
the majority of the genes presented encoded for proteins
involved in 104 KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathways. The top 12 pathways with the
highest number of genes involved are shown in Table 1.
We have divided some genes into functional categories
and have presented examples of some of them in Table
2. These data showed that a large number of the down
regulated genes are involved in metabolic pathways
(Table 2). There was down regulation of some of the
genes involved in the mitochondrial transport system
(Table 2). Furthermore, there was differential down reg-
ulation of some of the genes involved in Ca2+ cycling
and in myocardial contraction and relaxation (Table 2)
in addition to down regulation of genes involved in glu-
tathione pathway (Figure 1). There was up regulation of
some components of the NADPH oxidase subunits
(gp91 by 2.2 fold, P < 0.03) and down-regulation of
SOD1 (3 fold, P < 0.001) (Figure 1).
Discussion
Some of the genes that we found markedly up- or down
regulated encode for proteins whose role in myocardial
physiology and pathophysiology is well defined. Other
genes are presently difficult to put in a pathophysiolgical
context. It is obviously impossible to examine in detail
functions and potential pathophysiological roles of all of
the identified alterations, therefore our discussion will
focus on selected genes whose expression was found
markedly altered and whose potential importance is sup-
ported by the existing literature.
Regulation of cardiac metabolic and structural genes
A large number of the down regulated genes are
involved in metabolic pathways. Interestingly, as seen in
Table 2, the majority of the genes in the citric acid cycle
and the respiratory chain are down regulated by many
fold decrease. The large down regulation of these genes
may be indicative of mitochondrial dysfunction in DM
dogs. In our previous studies [12], we have shown that
there is depressed modulation of O2 consumption by
endogenous NO in cardiac muscle from diabetic dogs.
However, in this recent study based on our gene expres-
sion profiling of cardiac tissues from DM dogs, there is
strong evidence of a dysfunction of the mitochondria in
this DM model. This was also evident by the down reg-
ulation of some of the genes involved in the mitochon-
drial transport system. Examples of these are shown in
Table 2. Of particular interest are mitochondrial import
receptor subunit TOM22, mitochondrial import stimula-
tion factor L subunit, mitochondrial 2-oxoglutarate/
malate carrier protein, glucose transporter type 1, vol-
tage-dependent anion-selective channel protein 3, malo-
nyl CoA-acyl carrier protein transacylase, translocase of
inner mitochondrial membrane 50 homolog. This con-
clusion supports previous observations by other investi-
gators that there is evidence for mitochondrial
dysfunction in the hearts from other models of diabetes
[13-15,21]. Savabi [21] showed that there were fewer
mitochondria in the hearts from diabetic rats and lower
O2 consumption rates in isolated mitochondria than
those from normal hearts. Other studies [16] also sug-
gested that there was depressed basal O2 consumption
by myocytes suspended in medium, decreased calcium
uptake by mitochondria, and reduced mitochondrial
membrane potential from diabetic rats. The decrease in
calcium uptake by mitochondria is also supported in
this study in dogs with DM. Table 2 shows examples of
some of the genes involved in Ca2+ cycling and in myo-
cardial contraction and relaxation. During the last dec-
ade there was accumulating evidence that alterations of
excitation-contraction coupling (EC) may play a critical
role in the pathophysiology of myocardial failure. Based
on our microarray data (Table 2), a large number of
genes involved in these processes are down regulated.
The level of mRNA of troponin I, troponin C, tropo-
myosin, calmodulin, ryanodine receptor type 2 (RyR)
and SERCA2 were significantly decreased in these ani-
mals. Troponin I has been shown to be very sensitive
and specific indicator of damage to the myocardium.
Another gene which was down regulated was phospho-
lemman which is a cardiac transmembrane protein.
Phospholemman has been shown to regulate ion chan-
nel activity [22]. It has been proposed that phospholem-
man regulates the Na/K pump in a manner analogous
to regulation of the calcium ATPase SERCA 2a by phos-
pholamban [22]. The net effect of these changes in gene
expression might be an overall decrease in both diastolic
and systolic ventricular function, which may be an adap-
tive mechanism to protect the surviving myocardium by
reducing its energy expenditure. Linke et al [17] and
Table 1 Shows the top 12 KEEG pathways with the
highest number of genes involved




Citrate cycle (TCA cycle) 6
Glutathione metabolism 6
Glycolysis/Gluconeogenesis 6
Regulation of actin cytoskeleton 6
Adherens junction 5
Calcium signaling pathway 5
Leukocyte transendothelial migration 5
PPAR signaling pathway 5
Wnt signaling pathway 5
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Table 2 Examples of some of the genes which are statistically significant in alloxan induced diabetes in dog hearts
Affy Ids Fold-change P Values Gene Title
Metabolic genes
Up-regulated
1604393_at 7.31 0.01 inorganic pyrophosphatase
Down-regulated
1582358_s_at -78.79 0.004 glyceraldehyde-3-phosphate dehydrogenase
1586136_x_at -77.17 0.006 cytochrome c oxidase, subunit VIb polypeptide 1
1604455_at -55.33 0.002 Creatine kinase M-type
1583489_s_at -54.19 0.009 NADH-ubiquinone oxidoreductase 23 kDa subunit, mitochondrial precursor (Complex I-23KD)
1589664_s_at -26.35 0.002 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c, isoform 1
1603350_x_at -25.11 0.003 Beta enolase (2-phospho-D-glycerate hydro-lyase)
1603755_at -24.59 0.005 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q reductase)
1586831_at -24.42 0.006 Phosphoglycerate mutase 2
1583253_at -22.94 0.006 NADH-ubiquinone oxidoreductase Fe-S protein 7
1604453_at -22.63 0.003 isocitrate dehydrogenase 2 (NADP+), mitochondrial
1594799_at -22.47 0.007 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase)
1583615_at -20.11 0.01 inositol polyphosphate-5-phosphatase, 40kDa
1588757_at -17.75 0.003 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7
1597725_s_at -17.63 0.006 3-hydroxyacyl-CoA dehydrogenase type II
1583148_at -17.39 0.008 ubiquinol-cytochrome c reductase core protein I
1583152_at -17.27 0.007 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa
1583193_s_at -15.89 0.003 isocitrate dehydrogenase 3, beta subunit isoform b precursor
1592397_at -15.24 0.009 succinate-CoA ligase, GDP-forming, alpha subunit
1588432_at -14.22 0.009 cytochrome c-1
1588302_at -13.55 0.004 ubiquinol-cytochrome c reductase subunit
1583550_s_at -13.55 0.008 Vacuolar ATP synthase 16 kDa proteolipid subunit
1585498_at -12.82 0.01 Glucose-6-phosphate isomerase (GPI)
1583430_at -12.64 0.01 Triosephosphate isomerase (TIM) (Triose-phosphate isomerase)
1585763_at -12.64 0.008 Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondrial precursor
1583348_x_at -12.55 0.006 cytochrome c oxidase, subunit VIb polypeptide 1
1604126_at -10.63 0.007 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial
1584695_at -7.84 0.003 succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
1604230_at -7.73 0.006 NADH dehydrogenase 1 beta subcomplex 4
1598523_at -6.02 0.01 Glucose-6-phosphate isomerase (GPI)
1589790_s_at -6.02 0.007 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa
1592755_s_at -5.24 0.008 Electron transfer flavoprotein-ubiquinone oxidoreductase
1588377_at -5.17 0.01 3-methyl-2-oxobutanoate dehydrogenase kinase
1598623_s_at -4.79 0.005 phosphofructokinase, muscle
1586218_at -4.76 0.004 Aldose reductase
1590058_s_at -4.56 0.002 creatine kinase, mitochondrial 2
1584362_at -4.44 0.01 NAD-dependent deacetylase sirtuin-3
1583716_at -4.03 0.004 aconitase 2, mitochondrial
Mitochondria proteins and transport
Down-regulated
1583895_x_at -71.51 0.008 ribosomal protein L29
1593894_at -22.78 0.01 Mitochondrial import receptor subunit TOM22 homolog
1587993_x_at -11.47 0.008 Inner membrane protein OXA1L, mitochondrial precursor (Oxidase assembly 1-like protein)
1585706_x_at -11.39 0.008 Inner membrane protein OXA1L, mitochondrial precursor (Oxidase assembly 1-like protein)
1588228_at -9.85 0.006 Mitochondrial 39 S ribosomal protein L23 (L23mt) (MRP-L23) (L23 mitochondrial-related protein)
1592554_at -9.06 0.004 14-3-3 protein epsilon (14-3-3E) (Mitochondrial import stimulation factor L subunit) (MSF L)
1586690_at -7.89 0.01 NTF2-related export protein 1
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Zhao et al [11,12] showed that in alloxan-induced dia-
betes in dogs there were no changes in LVSP and LV
dP/dt at rest. In view of the role of sarco/endoplasic
reticulum in the cardiac contraction and relaxation pro-
cess, the observed reduction in gene expression of
sarco/endoplasic reticulum calcium handling proteins
may explain the depressed cardiac performance in dia-
betic dogs. Although our sampling protocol focused on
the myocardium, others have also shown similar obser-
vations in vascular smooth muscle cells (VSMCs) [23].
Searls et al showed that the previously-reported reduced
Ca2+ signaling in VSMCs from diabetic animals is likely
to be due to the altered distribution and/or levels of Ca2
+ regulatory proteins including the IP3R Ca
2+ channels,
RyR and SERCA proteins [23].
Regulation of oxidative stress genes
A number of studies suggested that superoxide is
involved in the endothelial dysfunction in experimental
diabetic animals and patients with diabetes because
superoxide dismutase and other antioxidants could, at
least in part, restore the endothelial dysfunction. We
have previously shown that in conscious dogs with DM
that: 1) baseline CBF was significantly decreased, 2)
endothelium-dependent (ACh) coronary vasodilation
were impaired, and 3) reflex cholinergic NO-dependent
coronary vasodilation was selectively depressed. The
most likely mechanism responsible for the depressed
reflex cholinergic NO-dependent coronary vasodilation
was the decreased bioactivity of NO from the vascular
endothelium. Bradykinin reduced oxygen consumption
in normal dog heart in vitro and this was reduced in
type I DM [12]. The effect of bradykinin was restored
by apocynin, tempol or vitamin C; indicating a role for
NADPH oxidase derived superoxide. Interstingly, there
was up regulation of some components of the NADPH
oxidase subunits (gp91 by 2.2 fold, P < 0.03) and down-
regulation of SOD1 (3 fold, P < 0.001). Over the years,
decreased NO bioavailability has been proposed as one
of the determinants of vascular damage in diabetes.
Recently, Hamed et al have shown that NO and super-
oxide dismutase play roles in modulating endothelial
progenitor cell function in type 2 diabetes mellitus [24].
Oxidative stress is involved in the pathogenesis of dia-
betic complications in animal models and in humans
[3]. Many authors believe that the liver mitochondrial
Table 2 Examples of some of the genes which are statistically significant in alloxan induced diabetes in dog hearts
(Continued)
1585137_at -7.52 0.01 Mitochondrial 2-oxoglutarate/malate carrier protein (OGCP)
1586284_at -7.52 0.009 ATP synthase coupling factor 6, mitochondrial precursor (ATPase subunit F6)
1582738_at -7.26 0.01 FXYD domain containing ion transport regulator 1 (phospholemman)
1586934_at -7.11 0.008 Solute carrier family 2, facilitated glucose transporter, member 1 (Glucose transporter type 1)
1592219_s_at -4.44 0.01 transaldolase 1
Calcium uptake and myocardial contraction and relaxation
Up-regulated
1606083_at 4.44 0.007 protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha)
Down-regulated
1582664_s_at -48.50 0.004 troponin I type 3 (cardiac)
1582739_s_at -36.50 0.01 FXYD domain containing ion transport regulator 1 (phospholemman)
1586044_s_at -20.82 0.008 actinin, alpha 2
1585703_s_at -19.97 0.006 beta-actin///actin, gamma 1
1582670_s_at -16.56 0.006 myosin, light chain 2, regulatory, cardiac, slow
1592467_at -15.03 0.01 Tropomyosin 1 (alpha)
1605421_at -13.27 0.009 phosphodiesterase 1C, calmodulin-dependent 70kDa
1587427_at -11.24 0.008 ryanodine receptor 2 (cardiac)
1605889_at -9.85 0.004 Myosin, light polypeptide 2, regulatory, cardiac, slow
1605583_at -5.17 0.009 cardiac titin
1585044_x_at 5.13 0005 myosin, light polypeptide 6, alkali, smooth muscle and non-muscle
1589676_s_at -5.06 0.006 actin, alpha, cardiac muscle 1
1583557_at -4.86 0.008 Adenylyl cyclase-associated protein 1 (CAP 1)
1584317_at -4.86 0.005 smoothelin isoform c
1602057_s_at -4.50 0.01 calmodulin 1
1604456_at -4.44 0.004 troponin C, slow
1592238_s_at -2.40 0.01 SERCA2
Ojaimi et al. Cardiovascular Diabetology 2010, 9:43
http://www.cardiab.com/content/9/1/43
Page 6 of 10
dysfunction in diabetes is closely dependent on oxidative
stress which is enhanced in diabetic animals and
patients [25,26]. Long-term reactive oxygen species
exposure resulted in damage of mitochondrial proteins
that caused disturbances in mitochondrial energy pro-
duction [27]. Some authors suggested that the loss of
mitochondrial respiration was essentially due to oxygen-
dependent inactivation of mitochondrial dehydrogenases
[28]. The mitochondrial dehydrogenase activities related
to complex I (NADH-dehydrogenase) and to complex II
(succinate dehydrogenase) were shown to decrease in
the diabetic rats. Interestingly, all of the above men-
tioned genes are also down regulated in our model pre-
sented in this study (Table 2).
Oxidative stress may be defined as an imbalance
between the production and degradation of reactive oxy-
gen species such as superoxide anion, hydrogen perox-
ide, lipid peroxides, and peroxynitrite. Enzymatic
inactivation of reactive oxygen species is achieved
mainly by glutathione peroxidase, superoxide dismutase,
and catalase [29]. The peroxidation of membrane lipids
is a major consequence of oxidative stress. The oxida-
tion of lipids, particularly phospholipids, has also been
suggested to be a significant chemical event in a variety
of pathological conditions, such as atherosclerosis,
ischemic injury, and carcinogenesis [30]. The formation
of lipid hydroperoxides (LOOHs) within the bilayer of
membranes disrupts membrane structure and function
[31], which subsequently leads to cell injury and death.
The repair of intracellular LOOHs can be carried out by
cytosolic glutathione peroxidase (cGPx) [32],
phospholipid hydroperoxide glutathione peroxidase
(PhGPx) [33], nonselenium GPx [34], or glutathione-S-
transferase (GST) [35].
In mammalian cells, glutathione and the glutathione
peroxidases constitute the principal antioxidant defense
system [36]. This is evident by the down regulation of
phospholipid hydroperoxide glutathione peroxidase, glu-
tathione peroxidase 1, glutathione reductase (mitochon-
drial precursor) and glutathione S-transferase. These
genes were down regulated by 3.7, 4.7, 3.5 and 2.9 fold
respectively (Figure 1). There are at least four different
glutathione peroxidases, all of which contain selenocys-
teine at their active sites [37]. Glutathione peroxidase 1,
the ubiquitous intracellular form and key antioxidant
enzyme within most cells, including the endothelium,
uses glutathione to reduce hydrogen peroxide to water
and lipid peroxides to their respective alcohols, and it
also acts as a peroxynitrite reductase [38]. In mice, glu-
tathione peroxidase 1 deficiency results in abnormal vas-
cular and cardiac function and structure [39]. Recent
studies in human have shown that decreased GPX-1
activity was observed in patients with coronary artery
disease (CAD) and those with acute myocardial infarc-
tion [40]. Espinola-Klein et al [41] have also shown that
decreased red blood cell GPX-1 activity is associated
with increased cardiovascular risk according to the
extent of atherosclerosis.
Glutathione is important in the regulation of the
redox state, and a decline in its tissue level has often
been considered to be indicative of increased oxidative
stress in diabetes. Glutathione (GSH) is present in most
Figure 1 Fold change of some genes involved in the bioactivity of NO that are statistically differentially regulated in the DM dogs. P
values are shown for each individual gene.
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mammalian cells and plays an important role in cellular
defense against oxidative stress by reducing protein dis-
ulfides and other cellular molecules. It also acts as a sca-
venger of free radicals of ROS [42]. GSH is synthesized
intracellularly by two GSH-synthesizing enzymes, g-glu-
tamylcysteine synthetase (g-GCS) and glutathione
synthetase. g-GCS catalyzes the rate-limiting step of
GSH synthesis [43]. In many cells, the GSH redox cycle
is catalyzed by both glutathione peroxidase and glu-
tathione reductase. During oxidative stress, the reduced
form of GSH is converted by glutathione peroxidase to
oxidized glutathione (GSSG). It was reported the pre-
sence of low GSH and high GSSG concentrations in
erythrocytes of diabetic patients [44] and in endothelial
cells of diabetic rabbits [16].
Two of the genes that were highly down-regulated in
DM were Myoglobin (Mb) and beta globin (Figure 1).
Previous studies have shown the role of myoglobin in
the antioxidant defense of the heart [45]. The lack of
myoglobin has been shown to cause a biochemical shift
in cardiac substrate utilization from fatty acid to glucose
oxidation [46]. In our previous studies [17] we have
shown that there was a shift in metabolic uptake by the
heart during development of alloxan-induced diabetes at
a time when myocardial NO production is already
decreased (3-4 weeks). This switch is a well know mar-
ker for heart failure. Studies have also suggested that
human Mb actively participates in the regulation of NO
[47]. Mb is a scavenger of bioactive NO through the
reaction NO with MbO2 to form metMb and nitrate
and may be the major mechanism of attenuating intra-
cellular NO bioactivity in cardiac muscle [45]. Flogel
et al showed that hearts from Mb-deficient (myo-/-)
mice were found to be more sensitive to the infusion of
reactive oxygen species (ROS, e.g., H2O2 and superox-
ide) in that depression of myocardial contractile force
was more pronounced as compared with WT controls.
Furthermore, Mb-deficient hearts released significantly
more ROS during IR, and this was accompanied by a
delayed functional and metabolic recovery after the
ischemic insult. It is obvious in this study that the array
data show a direct effect of diabetes on the heart by
impairing NO bioavailability through oxidative stress.
Therefore, our study is novel in that it represents the
first report of cardiac gene expression changes in a
canine model of alloxan-induced type 1 diabetes.
Limitations
Although the analysis of gene expression using oligonu-
cleotide microarrays is a powerful technique, limitations
warrant mention. Not all dog genes are represented on
the Affymetrix GeneChip® Canine Genome Arrays used
in this study. Furthermore, the annotations of high
number of the genes are still unknown and therefore
the knowledge that can be acquired from these experi-
ments remains incomplete. Up to now, this version of
the Canine array contains 7,340 complete annotated dog
genes. From our previous publications [19,20,48,49] in
addition to other reported publication [50], there seems
to exist a good correlation between oligonucleotide
microarray and qRT-PCR data. This correlation also
holds true when ratios of gene expression in different
tissues were compared for highly expressed genes and
not for those expressed at low levels due to the smaller
dynamic range of microarrays [50]. It is well known that
alloxan is specifically cytotoxic to the pancreatic ß cells.
However, the precise mechanism for this selectivity is
still not clear. Several studies in alloxan metabolism [51]
have documented that 45% of injected alloxan had been
excreted in the urine in 24 hours and 62% in 3 days.
Therefore, the gene expression data from this study
where dogs were sacrificed after 4 weeks of alloxan
injection are most likely due to the chronic effect of dia-
betes rather than the acute toxic effect of alloxan.
Conclusion
The gene expression profiling presented in this study
suggests a direct effect of type 1 diabetes on the heart
by impairing NO bioavailability through oxidative stress,
impairing calcium uptake by the mitochondrial trans-
port system, lipid peroxidases and down regulation of
citric acid cycle and the respiratory chain which are
indicative of mitochondrial dysfunction in DM dogs.
The order of these events is hard to elucidate and is yet
to be determined.
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